VEEV:NYSE
Veeva Systems Inc
$266.22
arrow_upward
+1.20%(+3.16) 1D
$266.61
arrow_upward
+0.15% (+0.39)bedtimeAfter hours
Closed: Nov 20, 4:02:03 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VEEV...
Open
$259.25
High
$268.96
Low
$259.25
Mkt. cap
43.10B
Avg. vol.
1.56M
Volume
1.60M
P/E ratio
43.54
52-wk high
$325.99
52-wk low
$148.05
EPS
$6.11
Beta
0.89
Shares outstanding
161.91M
No. of employees
8K
Open
$259.25
High
$268.96
Low
$259.25
Mkt. cap
43.10B
Avg. vol.
1.56M
Volume
1.60M
P/E ratio
43.54
52-wk high
$325.99
52-wk low
$148.05
EPS
$6.11
Beta
0.89
Shares outstanding
161.91M
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Veeva (VEEV) Stock May Be 17% Undervalued On Cash Flow Expectations
Trefis
·
1 day ago
Why Is Veeva Stock Falling?
Barchart.com
·
1 day ago
Veeva Systems Stock: Analyst Estimates & Ratings
The Motley Fool
·
2 days ago
Prediction: This Software-as-a-Service Stock Will Beat the Market Through 2031
Profile
Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry. Its products are used to track all aspects of drug development and pharmaceutical manufacturing.
The company has 1,552 customers including Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck & Co., Novartis, Alkermes plc, Alnylam Pharmaceuticals, bluebird bio, and Idorsia. Wikipedia
About Veeva Systems Inc
CEOPeter Gassner
Employees7.93K
Founded2007
HeadquartersPleasanton, California, United States
SectorHealth Care
Industry-
Websiteveeva.com
Analyst ratings
Based on 25 analysts giving stock ratings to VEEV in the past 3 months
Buy
Buy
18
Hold
6
Sell
1
12-month forecast
Based on 25 Wall Street analysts offering 12 month price targets for VEEV in the last 3 months.
Highest
Current $266.22
$400.00 (+50.25%)
Average
$319.57 (+20.04%)
Lowest
$180.00 (-32.39%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Taylor McGinnis UBS | Hold | Initiated | $310.00 | +16.4% | 11/19/2026 |
David Grossman Stifel Nicolaus | Buy | Maintained | $340.00 | +27.7% | 11/19/2026 |
Stan Berenshteyn Wells Fargo | Buy | Maintained | $400.00 | +50.3% | 11/17/2026 |
Saket Kalia Barclays | Buy | Maintained | $375.00 | +40.9% | 11/11/2026 |
Rishi Jaluria RBC Capital | Buy | Maintained | $365.00 | +37.1% | 11/11/2026 |
Jailendra Singh Truist Financial | Buy | Maintained | $360.00 | +35.2% | 11/09/2026 |
David Hynes Canaccord Genuity | Hold | Maintained | $315.00 | +18.3% | 11/09/2026 |
David Larsen BTIG | Buy | Reiterated | $360.00 | +35.2% | 11/09/2026 |
Craig Hettenbach Morgan Stanley | Hold | Maintained | $275.00 | +3.3% | 11/06/2026 |
David Windley Jefferies | Buy | Maintained | $375.00 | +40.9% | 11/06/2026 |
Karl Keirstead UBS | Hold | Maintained | $325.00 | +22.1% | 11/06/2026 |
Sean Dodge BMO Capital | Hold | Maintained | $300.00 | +12.7% | 11/06/2026 |
Steven Valiquette Mizuho Securities | Buy | Maintained | $345.00 | +29.6% | 10/29/2026 |
Joseph Vruwink Robert W. Baird | Buy | Maintained | $350.00 | +31.5% | 10/26/2026 |
Unknown Analyst CFRA | Buy | Upgraded | - | - | 09/16/2026 |
Charles Rhyee TD Cowen | Buy | Reiterated | $283.00 | +6.3% | 09/15/2026 |
Alexei Gogolev J.P. Morgan | Buy | Maintained | $299.00 | +12.3% | 09/01/2026 |
Tyler Radke Citi | Hold | Maintained | $273.00 | +2.5% | 08/28/2026 |
Brian Peterson Raymond James | Buy | Maintained | $330.00 | +24% | 08/27/2026 |
Kenneth Wong Oppenheimer | Buy | Reiterated | $325.00 | +22.1% | 08/27/2026 |
Gabriela Borges Goldman Sachs | Sell | Maintained | $180.00 | -32.4% | 08/26/2026 |
Kirk Materne Evercore ISI | Hold | Maintained | $250.00 | -6.1% | 08/27/2026 |
Ryan MacDonald Needham | Buy | Reiterated | $310.00 | +16.4% | 08/27/2026 |
Tamjid Chowdhury Guggenheim | Buy | Maintained | $310.00 | +16.4% | 08/27/2026 |
Billy Fitzsimmons Piper Sandler | Buy | Maintained | $320.00 | +20.2% | 08/27/2026 |
Dylan Becker William Blair | Buy | Maintained | - | - | 08/27/2026 |
John Difucci Guggenheim | Buy | Initiated | $232.00 | -12.9% | 07/22/2026 |
Unknown Analyst Guggenheim | Buy | Initiated | $232.00 | -12.9% | 07/22/2026 |
Martin Yang Oppenheimer | Buy | Reiterated | $225.00 | -15.5% | 06/04/2026 |
Hannah Rudoff Piper Sandler | Buy | Maintained | $235.00 | -11.7% | 06/04/2026 |
Adam Hotchkiss Goldman Sachs | Sell | Maintained | $165.00 | -38% | 06/04/2026 |
Unknown Analyst Stephens | Buy | Maintained | $324.00 | +21.7% | 03/05/2026 |
Bradley Sills Bank of America Securities | Hold | Maintained | $304.00 | +14.2% | 03/04/2026 |
Next call in 12 days
Thu, Dec 3, 5:00 PM
Fiscal period
Q3 2027
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.34
Revenue / Est. (USD)
- / 935.16M
Fiscal Q3 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
Revenue | 811.24M | 835.95M | 882.95M | 927.96M |
Cost of goods sold | 199.46M | 213.48M | 220.92M | 232.01M |
Cost of revenue | 199.46M | 213.48M | 220.92M | 232.01M |
Research and development expenses | 191.88M | 198.79M | 208.32M | 222.92M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 179.04M | 177.80M | 180.59M | 198.02M |
Operating expense | 370.92M | 376.60M | 388.91M | 420.93M |
Total operating expenses | 570.38M | 590.08M | 609.84M | 652.94M |
Operating income | 240.85M | 245.88M | 273.11M | 275.02M |
Other non operating income | - | 934.00K | - | - |
EBT including unusual items | 312.79M | 317.54M | 347.53M | 349.53M |
EBT excluding unusual items | 312.79M | 315.70M | 345.74M | 349.53M |
Income tax expense | 76.58M | 73.33M | 86.59M | 76.10M |
Effective tax rate | 24.48% | 23.09% | 24.92% | 21.77% |
Other operating expenses | - | - | - | - |
Net income | 236.20M | 244.20M | 260.94M | 273.43M |
Net profit margin | 29.12% | 29.21% | 29.55% | 29.47% |
Earnings per share | 2.04 | 2.06 | 2.24 | 2.35 |
Interest and investment income | 71.93M | 74.35M | 70.63M | 72.51M |
Interest expense | - | - | - | - |
Net interest expenses | 71.93M | 74.35M | 70.63M | 72.51M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 250.56M | 254.19M | 284.70M | 285.89M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events